Navigation Links
BioCryst Updates Peramivir Clinical Development Plan
Date:1/23/2008

he development and commercialization of forodesine HCl in markets across Europe, Asia, Australia and certain neighboring countries. In February 2007, BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection may not be correct, that HHS and the FDA may not agree with our analysis, that HHS may further condition, reduce or eliminate funding of the peramivir program, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in CTCL may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that Bio
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
2. BioCryst Provides Forodesine HCl Update
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 Galmed Pharmaceuticals Ltd. ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, announced today ... the FDA, approved its request for Fast Track ... treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... N.J. , Sept. 23, 2014  MEDIMETRIKS ... and William Resnick have been elected ... Mr. Lary, who will serve ... financial and investment experience to the Company.  Mr. ... Capital Advisors, LLC, a leading institutional investment firm.  ...
(Date:9/23/2014)... YORK , Sept 23, 2014  Vesselon, Inc. ... its Board of Directors, effective September 15, 2014. Dr. ... Inc. as its placement agent to market a private ... immediate and early stroke treatment. "Jurgen,s deep ... will be a great asset to Vesselon as we ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... May 16, 2011 Volcano Corporation (NASDAQ: VOLC ... Revascularization (EuroPCR) from May 17 – 20. Volcano,s focus will ... includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® ... use and value of Precision Guided Therapy in clinical practice ...
... PITTSBURGH, May 13, 2011 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) ... first company to have filed a substantially complete ANDA ... Capsules and was awarded 180 days of marketing exclusivity. ...
Cached Medicine Technology:Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 2Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 3Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 4
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... on Manhattan’s Upper West Side that embodies the ... Inhabiting Eden: Christians, Scripture and the Ecological Crisis, ... A. B. Rhodes Professor Emerita of Old Testament ... Bible for ancient wisdom that lends insight into ...
(Date:9/23/2014)... benefits of preventing a reduction in the rates ... today by the American College of Physicians (ACP). ... Medicaid Primary Care Pay Parity Program: Unless Congress ... Care Will Expire," explains why it is critical ... pediatricians (and their related subspecialists), family physicians, and ...
(Date:9/23/2014)... Singapore (PRWEB) September 23, 2014 ... aesthetic clinics in Singapore and Malaysia providing advanced ... revolutionary BB powder to its impressive skin care ... strengthen the skin’s defences against the evil forces ... a healthy glow simultaneously, this new addition is ...
(Date:9/23/2014)... 2014 (HealthDay News) -- The U.S. National Institutes ... funding in scientific trials to encourage researchers to ... The supplemental monies were provided to 82 ... immunology, cardiovascular physiology, neural circuitry, and behavioral health, ... "This funding strategy demonstrates our commitment to moving ...
(Date:9/23/2014)... and a researcher in UTSA,s South Texas Center for ... Ruhr University in Bochum, Germany to understand how humans ... week in an article published by the Proceedings ... is an acute infection caused by ingestion of food ... Vibrio cholerae . An estimated three to five million ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2
... of the commonly used stimulant methylphenidate (Ritalin) to speed ... the inhaled gas isoflurane, as previously reported, and to ... Massachusetts General Hospital (MGH) research team that reported the ... the May issue of Anesthesiology, and their ...
... HealthDay Reporter , THURSDAY, April 5 (HealthDay News) -- ... crops eaten by U.S. consumers is linked to shorter ... pesticides are known as organophosphates, which kill insects by ... nerve poisons during World War II, they can disrupt ...
... Serena Gordon HealthDay Reporter , THURSDAY, April 5 ... cells that potentially grow into tumors has been one of ... researchers from the Children,s Hospital of Philadelphia have generated a ... at least for stem cells destined for the digestive system ...
... largest multicenter clinical trial of children undergoing early-stage ... management did not significantly affect neurodevelopmental outcomes at ... were innate patient characteristics and general medical morbidity ... Children born with hypoplastic left-heart syndrome (HLHS) ...
... PhD, is the 2012 recipient of Kessler Foundation,s Joel A. ... the Field of Physical Medicine & Rehabilitation (PM&R). Dr. Whyte ... in West Orange on May 10. The award includes a ... Dr. Whyte is the founding director of Moss Rehabilitation ...
... Stem Cell , a Cell Press publication, have found a ... advance in mice suggests that a combination approach to therapy ... That,s in contrast to the vast majority of CML patients ... into remission only to see their cancer return again. It ...
Cached Medicine News:Health News:Recovery from propofol anesthesia may be sped by use of common stimulant 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 3Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 4Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 2Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 3Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 4Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 2Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 3Health News:Kessler Foundation names Dr. John Whyte recipient of Foundation's 2nd Annual DeLisa Award 2Health News:To prevent leukemia's dreaded return, go for the stem cells 2
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: